Dataset Information


Plasma exosomal miRNAs-based prognosis in metastatic kidney cancer.

ABSTRACT: Plasma exosomal miRNAs were evaluated for prognosis in an initial set of 44 metastatic renal cell cancer (mRCC) patients by RNA sequencing. Among ?3.49 million mappable reads per patient, miRNAs accounted for 93.1% of the mapped RNAs. 227 miRNAs with high abundance were selected for survival analysis. Cox regression analysis identified association of 6 miRNAs with overall survival (OS) (P<0.01, False discovery rate (FDR) < 0.3). Five of the associated miRNAs were quantified in an independent follow-up cohort of 65 mRCC patients by TaqMan-based miRNA assays. Kaplan-Meier analysis confirmed the significant OS association of three miRs; miR-let-7i-5p (P=0.018, HR=0.49, 95% CI=0.21-0.84), miR-26a-1-3p (P=0.025, HR=0.43, 95% CI=0.10-0.84) and miR-615-3p (P=0.0007, HR=0.36, 95% CI=0.11-0.54). A multivariate analysis of miR-let-7i-5p with the clinical factor-based Memorial Sloan-Kettering Cancer Center (MSKCC) score improved survival prediction from an area under the curve (AUC) of 0.58 for MSKCC score to an average AUC of 0.64 across 48-month follow-up time. The multivariate model was able to define a high-risk group with median survival of 14 months and low risk group of 39 months (P=0.0002, HR=3.43, 95%CI, 2.73-24.15). Further validation of miRNA-based prognostic biomarkers are needed to improve current clinic-pathologic based prognostic models in patients with mRCC.


PROVIDER: S-EPMC5609954 | BioStudies | 2017-01-01

REPOSITORIES: biostudies

Similar Datasets

2017-10-31 | GSE93175 | GEO
2014-01-01 | S-EPMC4113501 | BioStudies
2018-01-01 | S-EPMC6261038 | BioStudies
2015-01-01 | S-EPMC4428989 | BioStudies
1000-01-01 | S-EPMC5713295 | BioStudies
1000-01-01 | S-EPMC4334826 | BioStudies
1000-01-01 | S-EPMC5529487 | BioStudies
2017-01-01 | S-EPMC5544252 | BioStudies
1000-01-01 | S-EPMC5752475 | BioStudies
1000-01-01 | S-EPMC4694817 | BioStudies